不同病理类型及分期甲状腺癌中miR-1296、miR-637和miR-1243的表达研究

Expression of miR-1296,miR-637 and miR-1243 in Different Pathological Types and Stages of Thyroid Cancer

目的观察不同病理类型及分期的甲状腺癌(TC)患者癌组织中miR-1296、miR-637和miR-1243的表达情况,探讨miR-1296、miR-637和miR-1243与TC患者病理类型及分期的关系。方法收集2019年7月至2020年7月哈励逊国际和平医院收治的100例TC患者的临床资料。所有患者均接受病理检查,取患者癌组织、癌旁组织(>肿瘤边界2 cm以上)及正常甲状腺组织,采用反转录聚合酶链反应(RT-PCR)技术检测不同组织中miR-1296、miR-1243、miR-637水平,并结合患者临床病理特征进行分析。结果TNM分期为Ⅲ—Ⅳ期、淋巴结转移、病理类型为分化型患者miR-1296、miR-637和miR-1243的相对表达量分别低于TNM分期为Ⅰ—Ⅱ期、无淋巴结转移、病理类型为甲状腺髓样癌、未分化型患者(P<0.05);癌组织miR-1296、miR-637、miR-1243相对表达量低于癌旁组织、正常组织(P<0.05)。二元logistic回归分析结果显示,miR-1296、miR-637和miR-1243高表达是TC患者病理类型为未分化型、临床分期为Ⅰ—Ⅱ期的保护因素(OR<1,P<0.05)。100例TC患者随访24个月,其中预后良好75例(75.00%),预后不良25例(25.00%);预后良好组miR-1296、miR-637和miR-1243相对表达量高于预后不良组(P<0.05);绘制ROC曲线结果显示,miR-1243相对表达量及联合检测预测TC患者预后不良的AUC均>0.70,有一定预测价值,其中联合检测最高。结论癌组织中miR-1296、miR-637和miR-1243相对表达量与TC患者病理类型及分期密切相关,三者可作为判断甲状腺癌病理类型及分期的分子标记物,进而指导临床治疗。

Objective To observe the expression levels of miR-1296,miR-637 and miR-1243 in thyroid cancer(TC)patients with different pathological types and stages,and analyze the relationship between miR-1296,miR-637 and miR-1243 and TC patients’pathological types and stages.Methods Clinical data of 100 TC patients admitted to Halexon International Peace Hospital from July 2019 to July 2020 were collected.All patients were subjected to pathological examination,and the patients’cancerous tissues,paracancerous tissues(>2 cm above the tumor border)and normal thyroid tissues were taken.Using reverse transcription polymerase chain reaction(RT-PCR)technology,the levels of miR-1296,miR-1243,and miR-637 in different tissues were detected and analyzed in conjunction with the clinicopathological characteristics of the patients.Results The relative expression levels of miR-1296,miR-637 and miR-1243 in patients with TNM stageⅢ-Ⅳ,lymph node metastasis,and pathological type of differentiated type was lower than those in patients with TNM stageⅠ-Ⅱ,no lymph node metastasis,and pathological type of medullary carcinoma of thyroid,and undifferentiated type,respectively(P<0.05);the relative expression levels of miR-1296,miR-637 and miR-1243 in cancer tissues was lower than those in paracancerous tissues and normal tissues(P<0.05).The results of binary logistic regression analysis showed that high expression of miR-1296,miR-637,and miR-1243 were protective factors for TC patients with pathological type of undifferentiated type and TNM stageⅠ-Ⅱ(OR<1,P<0.05).100 TC patients were followed up for 24 months,of which 75 cases(75.00%)had a good prognosis and 25 cases(25.00%)had a poor prognosis;the relative expression levels of miR-1296,miR-637 and miR-1243 in the good prognosis group were higher than those in the bad prognosis group(P<0.05).The results of ROC curves showed that the AUCs of miR-1243 relative expression and combined assay for predicting poor prognosis in TC patients were both>0.70,which had some predictive value,with the combined assay being the highest.Conclusion The relative expression levels of miR-1296,miR-637 and miR-1243 in cancer tissues are closely related to pathological types and stages of TC patients,and all three can be used as molecular markers for determining the pathological type and stage of thyroid cancer,which in turn can guide clinical treatment.